journal article·2024-12Open access

Powder X-ray diffraction of acalabrutinib dihydrate Form III, C 26 H 23 N 7 O 2 (H 2 O) 2

James A. Kaduk, Megan M. Rost, Anja Dosen, Thomas N. Blanton

Powder Diffraction· Volume 39· Issue 4

Abstract

The crystal structure of acalabrutinib dihydrate Form III has been refined using synchrotron X-ray powder diffraction data, and optimized using density functional techniques. Acalabrutinib dihydrate Form III crystallizes in space group P 2 1 (#4) with a = 8.38117(5), b = 21.16085(14), c = 14.12494(16) Å, β = 94.5343(6)°, V = 2497.256(20) Å 3 , and Z = 4 ( Z′ = 2) at 295 K. The crystal structure consists of herringbone layers parallel to the ac -plane. Hydrogen bonds between the acalabrutinib and water molecules generate a three-dimensional framework. Each water molecule acts as a donor in two hydrogen bonds and as an acceptor in at least one hydrogen bond. Amino groups and pyridine N atoms link the acalabrutinib molecules into dimers. The powder pattern has been submitted to ICDD for inclusion in the Powder Diffraction File™ (PDF®).
Source: crossref · Quality: baseline

Research context

OpenAlex topics: X-ray Diffraction in Crystallography · Synthesis of Tetrazole Derivatives · Multicomponent Synthesis of Heterocycles

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (14)

Show source-provided references
1. 2023
2. 10.1107/S205252061800233010.1107/S2052520618002330 ↗
3. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
4. 10.1063/1.296926010.1063/1.2969260 ↗
5. 10.1017/S088571561800082910.1017/S0885715618000829 ↗
6. 10.1016/0927-0256(96)00008-010.1016/0927-0256(96)00008-0 ↗
7. 10.1021/acs.jctc.2c0095810.1021/acs.jctc.2c00958 ↗
8. Crystal Impact. 2023. Diamond. V. 5.0.0. Crystal Impact - Dr. H. Putz & Dr. K. Brandenburg.
9. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
10. 10.3749/canmin.46.5.150110.3749/canmin.46.5.1501 ↗
11. 10.1017/S088571561900081210.1017/S0885715619000812 ↗
12. Blatter, F. , Ingallinera, T. , Barf, T. , Aret, E. , Krejsa, C. , and Evarts, J. . 2017. “Crystal Forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-A]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide.” United States Patent 9,796,721 B2.
13. 10.1107/S090904950801843810.1107/S0909049508018438 ↗
14. 10.1107/S160057671901409210.1107/S1600576719014092 ↗